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Abstract
Background: Cerium oxide (CeO2) nanoparticles used as a diesel fuel additive can be emitted into the ambient air
leading to human inhalation. Although biological studies have shown CeO2 nanoparticles can cause adverse health
effects, the extent of the biodistribution of CeO2 nanoparticles through inhalation has not been well characterized.
Furthermore, freshly emitted CeO2 nanoparticles can undergo an aging process by interaction with other ambient
airborne pollutants that may influence the biodistribution after inhalation. Therefore, understanding the
pharmacokinetic of newly-generated and atmospherically-aged CeO2 nanoparticles is needed to assess the risks to
human health.
Methods: A novel experimental system was designed to integrate the generation, aging, and inhalation exposure
of Sprague Dawley rats to combustion-generated CeO2 nanoparticles (25 and 90 nm bimodal distribution). Aging
was done in a chamber representing typical ambient urban air conditions with UV lights. Following a single 4-hour
nose-only exposure to freshly emitted or aged CeO2 for 15 min, 24 h, and 7 days, ICP-MS detection of Ce in the
blood, lungs, gastrointestinal tract, liver, spleen, kidneys, heart, brain, olfactory bulb, urine, and feces were analyzed
with a mass balance approach to gain an overarching understanding of the distribution. A physiologically based
pharmacokinetic (PBPK) model that includes mucociliary clearance, phagocytosis, and entry into the systemic circulation
by alveolar wall penetration was developed to predict the biodistribution kinetic of the inhaled CeO2 nanoparticles.
Results: Cerium was predominantly recovered in the lungs and feces, with extrapulmonary organs contributing less
than 4 % to the recovery rate at 24 h post exposure. No significant differences in biodistribution patterns were found
between fresh and aged CeO2 nanoparticles. The PBPK model predicted the biodistribution well and identified
phagocytizing cells in the pulmonary region accountable for most of the nanoparticles not eliminated by feces.
Conclusions: The biodistribution of fresh and aged CeO2 nanoparticles followed the same patterns, with the highest
amounts recovered in the feces and lungs. The slow decrease of nanoparticle concentrations in the lungs can be
explained by clearance to the gastrointestinal tract and then to the feces. The PBPK model successfully predicted the
kinetic of CeO2 nanoparticles in various organs measured in this study and suggested most of the nanoparticles were
captured by phagocytizing cells.
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Background
Engineered nanoparticles have emerged as innovative
materials that hold multiple promising features when
compared to their bulk counterparts [1]. Industrial, com-
mercial, medical and consumer applications of nanoma-
terials have raised concerns about the potential human
health impacts, given toxic effects of nanoparticles in
animal studies [2–5]. This paper focuses on inhalation
exposure and the systemic distribution of cerium oxide
(CeO2) nanoparticles, which are mainly used as a diesel
fuel additive to reduce particulate emissions [6, 7] and
can be released to the environment by diesel engines.
Several in vitro and in vivo studies have shown CeO2
nanoparticles can generate reactive oxygen species that
induce oxidative stress and inflammatory responses [8,
9]. To better understand the toxic effects of CeO2 nano-
particles, it is necessary to first characterize the biodistri-
bution of CeO2 nanoparticles in the entire body.
Several studies have shown intravenously injected
CeO2 nanoparticles in rats could be found in all major
organs up to 90 days after injection [10–12]. An intratra-
cheal instillation study found that besides the lungs, the
largest amount of instilled CeO2 nanoparticles was in
the feces in the first 2 days after exposure [13]. Recently
conducted inhalation studies on CeO2 nanoparticles
showed the lungs are the major deposit organ while
CeO2 nanoparticles could penetrate from the lungs into
the systemic circulation as they were found in other
body organs [8, 14]. However, these inhalation studies
did not include feces and failed to provide a more com-
prehensive mass balance of the inhaled dose of CeO2
nanoparticles. In addition, diesel fuel combustion emits
CeO2 nanoparticles directly into the air where the parti-
cles can interact with reactive gases found in the urban
air environment. There is therefore a need to characterize
the environmental transformation and physicochemical
properties of aged CeO2 nanoparticles accounting for the
interactions with UV radiation and the typical reactive
gases found in ambient air, and to compare the biodistri-
bution of aged CeO2 nanoparticles with the biodistribu-
tion of freshly-combusted CeO2 nanoparticles.
To better understand exposure, provide insights on
the main mechanisms responsible for biodistribution
and possibly extrapolate biobehavior from rodent models
to humans, it is useful to complement biodistribution
experimental data with pharmacokinetic modeling.
Physiologically based pharmacokinetic (PBPK) models
have been used to study and predict the biodistribution
of chemicals inside the body for decades [15]. Several
PBPK models have been specifically developed for nano-
particles [16–19] but failed to specifically address the
role of phagocytosis, which has been observed as a key
process of nanoparticle biodistribution [20–22]. Li et al.
[23] built a whole-body PBPK model that incorporated
phagocytosis, but the model was limited to intravenous
injection of nanoparticles. Kolanjiyil and Kleinstreuer
[24] developed a multicompartment model for inhaled
nanoparticles, but the model was based on relatively
simple transfer rates between each compartment and
therefore lacked physiological significance. PBPK models
for inhalation exposure of silver nanoparticles and for
instillation of gold nanoparticles have been developed by
Bachler et al. [25, 26]. These models have one compart-
ment for the respiratory system and the latter lack trans-
location to the gastrointestinal tract via mucus escalator,
which has been indicated as an important elimination
pathway for cerium nanoparticles [13]. In the PBPK
model by Sweeney and colleagues [27], the researchers
extended a previous lung model to include systemic ex-
posure of silver, titanium dioxide and iridium nanoparti-
cles. The model divided the respiratory system into
three compartments and allowed uptake to the olfactory
system via the nose and in tissue nanoparticles could be
quasi-irreversibly sequestered and cleared to feces. Cur-
rently, there is no detailed PBPK model describing the
biodistribution of inhaled CeO2 nanoparticles. There is
therefore a need for developing a PBPK model parame-
terized for CeO2 including deposition in the respiratory
system and translocation/excretion.
The objectives of this study are:
1. Generate and characterize both fresh and UV-light
aged CeO2 nanoparticles under general outdoor air
composition.
2. Measure the biodistribution of CeO2 nanoparticles
in rat following an inhalation study, including the
main organs and feces and analyze the mass balance.
3. Develop, parameterize, and evaluate a PBPK model
that combines pulmonary deposition with internal
biodistribution to predict the biodistribution kinetic
of inhaled CeO2 nanoparticles in rats.
Methods
Experimental apparatus
Figure 1 shows the schematic of the experimental appar-
atus consisting of a nanoparticle generation facility, a
photochemical aging chamber, a series of instruments to
characterize the aerosol flow, and a nose-only inhalation
exposure chamber for rats.
Generation of CeO2 nanoparticles
CeO2 nanoparticles were generated using the University
of Michigan combustion synthesis (UMCS) facility which
was transported to Michigan State University for the
animal exposure studies. The UMCS facility uses a
multi-element H2/O2 diffusion flame burner to provide a
high-temperature oxidizing environment for cerium
acetate (cerium (III) acetate hydrate; Sigma-Aldrich,
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99.99 % trace metals basis) precursor decomposition,
oxidation, and particle formation. The burner was oper-
ated continuously to generate appropriate quantities of
nanoparticles for the exposure studies and analysis. Fur-
ther information on the synthesis facility can be found in
Bakrania et al. [28, 29], Miller et al. [30], Hall et al. [31],
and (Fatouraie et al.: Combustion-generated particle syn-
thesis and delivery system for inhalation exposure studies:
case study for ceria nanoparticles, submitted).
Photochemical chamber
The atmospheric reaction chamber is a 500-L fluorinated
ethylene propylene Teflon bag designed in collaboration
with Ingeniven Inc. (North Hampton, NH, United States).
Thirty (UVA-340) fluorescent lamps (40 W each) were
used to simulate sunlight in the short wavelength region
from 365 nm to the solar cutoff of 295 nm. The lamps
were placed beside the chamber to simulate ~250 W/m2
of direct UV flux in the chamber, which is equivalent to
five times the solar UV flux. Reflections from the interior
surface of the enclosure are expected to significantly in-
crease this figure and actual UV flux levels were measured
with a UV meter. To simulate atmospheric aging condi-
tions, the lamps were turned on simultaneously with the
generation and exposure of CeO2 nanoparticles, with a
high UV intensity of ~250 W/m2 of direct UV flux at a
peak emission wavelength of 340 nm to accelerate aging
and a residence time of the CeO2 nanoparticles of ap-
proximately 15 min in the aging chamber.
Nanoparticle characterization
A scanning mobility particle sizer (SMPS) with an elec-
trostatic classifier (TSI-3080, TSI Inc., Shoreview, MN,
USA) was used to monitor the aerosol number density
and particle size distribution as a function of time during
the animal exposure studies. Specifically, the size distri-
bution of the aerosol was monitored during the experi-
ments in real time using a differential mobility analyzer
Fig. 1 Schematic representation and photo of the experimental apparatus. The dimensions are not to scale. “lpm” stands for liters per minute. “R”
notations beside tubing connections indicate radius and the associated numbers are in meters. The “F” and “R” notations beside the carousel
represent filter pack and rat positions, respectively
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(DMA) (TSI-3081, TSI Inc., Shoreview, MN, USA) con-
nected to a condensation particle counter (CPC) (TSI-
3010, TSI Inc., Shoreview, MN, USA). The SMPS uses a par-
ticle size impactor filter to remove particles > ~0.5 μm in size.
Additionally, a three-stage cascade impactor filter with cut-
off stages at 2.5, 1, and 0.5 μm (Sioutas Impactor, SKC Inc.,
EightyFour, PA,USA)was incorporatedafter thephotochem-
ical chamber, upstream of the exposure carousel, filter packs
and SPMS, to remove larger particles and agglomerates >
~0.5 μm in size. The midpoint particle mobility diameter re-
corded by the SMPS was used to calculate the equivalent
spherical volume of the aerosol, which was multiplied by the
theoretical density of CeO2 (7.13 g/cm
3) to estimate the aver-
age mass concentration. The mass concentration calculated
from SMPS data was compared with the physical sampling
measurementsbasedon the filter packs.
Gas sampling (GS) was used to measure the NOx, CO,
O3, and CO2 levels in the carrier gas of nanoparticles.
The NOx (NO and NO2 measured using a chemilumin-
escence analyzer, Thermo Scientific 42C, Thermo Fisher
Scientific Inc) and O3 (measured using a UV photometric
analyzer, Thermo Scientific 49C, Thermo Fisher Scientific
Inc, USA) were by-products of the combustion process
used to generate the ceria nanoparticles, and also repre-
sent gases found at ambient conditions in urban envi-
ronments. Additional measurement of post combustion
O2 levels were performed using an emission analyzer
(MEXA-584 L, HORIBA Instruments, Ann Arbor, MI,
USA) to ensure the oxygen concentration was at atmos-
pheric levels, i.e. near 20 % on a mole fraction basis.
The mass of nanoparticles during each exposure study
was measured using filter pack assemblies. Four 47-mm
Teflon (PTFE) filters (Gelman Science) in Teflon/Teflon-
coated aluminum filter packs were attached to two ports
of the exposure chamber to determine the total nanoparti-
cle mass deposited during sampling times corresponding
to the exposure studies. The filter packs were used accord-
ing to the Federal Reference Method [32]. Four pumps
were used to control the flow rates to the exposure carou-
sel, the filter packs, the SMPS and the GS system. Add-
itional details on the aerosol transport system, including
dimensions and flow rates, are described by (Fatouraie et
al.: Combustion-generated particle synthesis and delivery
system for inhalation exposure studies:case study for ceria
nanoparticles, submitted).
Transmission electron microscopy (TEM) was per-
formed at the University of Michigan electron micro-
beam analysis laboratory using a high resolution
electron microscope (JEOL 3011, JEOL USA Inc., Pea-
body, MA, USA) in order to characterize the morph-
ology and size distribution of the nanoparticles. The
nanoparticles were sampled on copper grids (carbon
film, 300 mesh copper, Electron Microscopy Sciences,
Hatfield, PA, USA) placed in the aerosol flow after the
impactor filter. Bulk properties such as crystalline struc-
ture and the average crystallite size were analyzed using
powder x-ray diffraction (XRD) equipment (Bruker D8
Discover with GADDS, BRUKER AXS Inc., Madison,
WI, USA). Details on the sample preparation for the
nanoparticle materials analysis are described by (Fatouraie
et al.: Combustion-generated particle synthesis and deliv-
ery system for inhalation exposure studies:case study for
ceria nanoparticles, submitted).
Animal study design
Animals and inhalation exposure
Male Sprague-Dawley rats weighting 200–235 g, 9 weeks
of age, were obtained from Charles River Laboratories
(Portage, MI, United States) and housed for at least
7 days in shoebox-style cages prior to experimental pro-
tocols with access to food and water ad libitum. Study
protocols were approved by the Institutional Animal
Care and Use Committee of Michigan State University,
an AAALAC accredited institution.
Rats were acclimated to nose-only restraining devices
(CH Technologies, Westwood, NJ, USA) for at least
4 days preceding exposure. For the experiments in this
study, nine rats were exposed to CeO2 nanoparticles in a
12-port nose-only exposure system (CH Technologies)
for a single 4-hour exposure. Two ports of the system
were used to collect nanoparticle samples and one port
was used to connect to the SMPS. The exposure envir-
onmental conditions were 25 ± 3 °C, 50 ± 15 % humidity,
and the dilution levels in the burner were controlled to
achieve oxygen concentration of 20 % on a mole fraction
basis with upper limits of 25 ppb for O3 and 50 ppb for
NOx. Two sets of experiments of nine rats per experi-
ment were used for both freshly-generated CeO2 nano-
particles and aged CeO2 nanoparticles. After exposure,
three rats each were sacrificed after 15 min, 24 h, and
7 days (n = 3 per time point per experiment). Blood,
lungs, liver, kidneys, heart, brain, olfactory bulb, spleen,
feces, and urine were collected for CeO2 nanoparticles
concentration analysis. Feces and urine were collected
only for the first 24 h post exposure. Gastrointestinal
tract (GI tract) samples were also collected for analysis
from the aged nanoparticles exposure experiments.
A separate pilot study was conducted to measure the
evolution of CeO2 nanoparticle concentrations in the
feces. Six rats were exposed to 770 ± 210 μg/m3 cerium
oxide nanoparticles for 5 h and feces were collected 1, 2,
4, 5, and 7-day post exposure using metabolic cages. Ex-
posure protocols are the same as described above.
Determination of CeO2 nanoparticle concentrations in
biological samples
All equipment and supplies used for trace element ana-
lysis were rigorously acid-cleaned. Detailed procedures
Li et al. Particle and Fibre Toxicology  (2016) 13:45 Page 4 of 20
on the sample digestion and analysis were documented
previously [33, 34]. In brief, all biological samples were
weighed and then acid-digested in concentrated nitric acid.
Sample extracts were then diluted and analyzed for cerium
using inductively coupled plasma–mass spectrometry (ICP-
MS) (ELEMENT2, Thermo Finnigan, San Jose, CA, USA).
The detection limit of the method is 0.002 ng/mL. The
background cerium levels in all sampled organs were deter-
mined in a preliminary study with two control rats which
were not exposed to the CeO2 nanoparticle aerosol and did
not undergo any sham exposure procedures. All back-
ground levels were below the detection limit.
The cerium concentration levels in all organs at all time
points for all four sets of experiments were normalized by
the corresponding exposure concentrations measured by
the filter packs. The data was then grouped into three time
points for fresh and aged nanoparticles with each time
point having a larger sample size. Shapiro-Wilk test was
performed to confirm the data was following normal distri-
bution before A two-tailed heteroscedastic Student t-test
was then performed to examine the null hypothesis of no
significant difference between the biodistribution of fresh
and aged nanoparticles for each time point and organ.
PBPK modeling
Model framework
This PBPK is based on our previous version for intraven-
ously injected nanoparticles already published [23, 35], ex-
tended for inhalation exposure by including deposition in
the respiratory system and transfer to the GI tract. The
present PBPK model consists of ten compartments: arterial
blood, venous blood, lungs, spleen, liver, kidneys, heart, brain,
GI tract, and the rest of the body. All compartments are inter-
connected via systemic circulation (Fig. 2). Within each organ
compartment, there are three sub-compartments represent-
ing capillary blood, tissue, and phagocytizing cells (PCs). The
arterial blood and venous blood compartments also have PCs
sub-compartments. In the experiments, nanoparticles were
inhaled by the rats immediately at the start of exposure to the
aerosol, and the model similarly started predicting uptake of
particles immediately upon exposure. A similar structure
used by Sweeney and co-workers was adopted to describe
deposition and clearance in the respiratory system [27].
Following inhalation, the nanoparticles are deposited into
three regions of the respiratory system: the upper airway,
the tracheobronchial region, and the pulmonary region.
The deposition fractions are fitted by observed amounts
in different organs, with the same values used for all simu-
lations of the four studies.
After being deposited in the upper airway, nanoparti-
cles can migrate either to the brain via the olfactory
bulb, or to the GI tract by being swallowed. Nanoparti-
cles deposited in the tracheobronchial region can be
transferred to the pharynx in the upper airway by
mucociliary clearance, then swallowed to the GI tract
lumen and eventually excreted via feces. After penetrat-
ing the interstitium of the lungs, nanoparticles can enter
the systemic circulation system and migrate to other or-
gans. PCs loaded with nanoparticles in the pulmonary
region can also be transferred to the upper airway by
mucociliary transportation.
The exchange of nanoparticles between blood and tis-
sue in each organ is described as a flow- and diffusion-
limited process. The flow-limited process is controlled
by a permeability coefficient, which limits the effective
blood flow [15]. We assume one permeability coefficient
for the brain, a different permeability coefficient for the
liver and the spleen, and another different permeability
coefficient for the other organs [35]. The permeability
coefficient for the brain compartment is expected to be
much lower under the assumption of a highly efficient
blood-brain barrier as observed by Hardas et al. [12].
The diffusion-limited process is controlled by the tissue:-
blood partition coefficient and assumed to be the same
for all organ tissues [23].
A fraction of the nanoparticles entering the tissue
are sequestrated by PCs until the PCs are eventually
saturated. All PCs are assumed to behave the same but
the abundance of PCs in the tissues differ. The effect-
ive uptake rate by PCs is a function of the maximum
uptake rate and decreases as the PCs become satu-
rated. The maximum uptake rate is the same for all
compartments except for the spleen, due to its mesh-
like structure that could trap nanoparticles in the
spleen marginal zones and delay their contact with the
splenic PCs [36, 37]. Nanoparticles can also re-enter
the tissue after desorption from PCs by processes such
as exocytosis [38, 39]. The uptake capacity and uptake
rate for each PC may vary between different nanoparti-
cles, while the relative abundance of PC densities in
different organs was taken to be the same for all types
of nanoparticle.
Excretion of nanoparticles occurs from the GI tract,
liver tissue, and the capillary blood of the kidneys. Deg-
radation of CeO2 nanoparticles is considered negligible
for the time-scale of this study.
Main mathematical description of the model
We present here two main model equations describing
the mass balances of a tissue t and of the PCs in this tis-
sue. A more comprehensive derivation of the mathem-
atical representation of the model is given in Additional
file 1.
The dynamics of the nanoparticles in the tissue sub-
compartment can be predominantly described by two
mechanisms: 1) the transfer between arterial blood and
venous blood and; 2) the interaction with the PCs. In
certain organs, excretion of nanoparticles occurs as a
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clearance route. The equation describing these pro-
cesses is:
dMt
dt
¼ χα  Qt
1þ χα
  Cart−Ct=Pð Þ
zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{transfer between arterial=venous blood
− Wt  Ct  kt;ab−Mt;m  kde
 zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{interaction with PCs
−
dMe;ex
dt
zfflffl}|fflffl{clearance by excretion
ð1Þ
where,
Mt [μg] – Amount of nanoparticles in the tissue of
organ t.
χα [unitless] – Permeability coefficient between capillary
blood and tissue.
Qt [mL per hour] – Regional blood flow in organ t.
Cart [μg per g] – Concentration of nanoparticles in the
arterial blood.
Ct [μg per g] – Concentration of nanoparticles in the
tissue of organ t.
P [unitless] – Partition coefficient of nanoparticles
between tissue and blood.
Wt [g] – Weight of organ t.
Mt,m [μg] – Amount of nanoparticles captured by the
PCs in organ t.
kt,ab [per hour] – Current uptake rate of nanoparticles
by the PCs in organ t.
kde [per hour] – Desorption rate of nanoparticles from
the PCs to tissue.
Me,ex [μg] – Amount to excreta from source e. e only
applies to tissue in the liver and capillary blood in the
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Fig. 2 Schematic representation of the nanoparticle PBPK model developed in this study for inhalation, with sub-compartments of phagocytizing
cells (PCs) in each tissue. Arrows represent the direction of various pathways for the nanoparticles to migrate from one location to another. Nanoparticles
may not be endocytosed by PCs nor migrate into the tissue matrix and exist in a “free” state in the tracheobronchial and pulmonary region of the lung
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kidneys. The elimination of nanoparticles directly from
the GI tract is described separately (Additional file 1).
The change in mass of the nanoparticles in the PCs is
the uptake from the tissue minus desorption from the
PCs back to tissue. The uptake rate kt,ab will decrease as
the amount of nanoparticles captured approaches the
total PCs saturation level, characterized by the PCs up-
take capacity per unit weight. The equation describing
these behaviors is:
dMt;m
dt
¼ Wt  Ct  kab0 1− Mt;mMt;cap Wt
 zfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl}|fflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflfflffl{uptake from tissue
− Mt;m  kde
zfflfflfflfflfflfflffl}|fflfflfflfflfflfflffl{desorption back to tissue
ð2Þ
where,
kab0 [per hour] – Maximum uptake rate by the PCs
(the same for all organs except the spleen [35]).
Mt,cap [μg per g] – PCs uptake capacity for nanoparticles
per organ t weight, which is determined as the PCs num-
ber per organ weight (nanoparticle type independent)
multiplied by the maximum uptake capacity in individual
PCs (the same for all organs except the spleen) [35].
In addition, the model divides the respiratory system
into three compartments; the pulmonary, tracheobron-
chial, and upper airway regions. In the pulmonary re-
gion, nanoparticles translocate into systemic circulation
(described by first order kinetics) or become engulfed by
PCs residing in the alveolar sacs (Eq. 2). The PCs in the
pulmonary region transport nanoparticles to the tra-
cheobronchial region for further clearance by a mucus
escalator to the larynx and the GI tract, which is de-
scribed by first order kinetics. In the upper airway re-
gion, the nanoparticles are cleared mainly to the GI
tract, but also transferred to the olfactory system using
first order transfer rates. More detailed information can
be found in Additional file 1.
Model implementation
The PBPK model was implemented in Berkeley Madonna™
version 8.3.18 (Berkeley, CA) and acslX™ version 3.0.2.1
(Huntsville, AL). Parameters with unknown values were
optimized by fitting the model parameters and comparing
the model results with experimental data obtained from
this study using the Nelder-Mead method in acslX™ with
termination criteria set as 0.001, 0.001, and 1000 for par-
ameter stop tolerance, object function stop, and maximum
iteration. To create the most parsimonious model pos-
sible, common generic parameter values were used for
most organs. Differentiated parameters between compart-
ments were only used when it was indispensable to ex-
plain the dynamics of the CeO2 concentrations in that
compartment in a physiologically meaningful way. The
fraction of residual capillary blood left in the organs when
analyzed for nanoparticle contents and the PCs uptake
capacities in the organs were taken from our previous
model, developed for intravenous injection [23] and tested
on various nanoparticles [35]. All other parameter values
were taken from the scientific literature [15, 40–43].
Values of all parameters are listed in Tables 1 and 2 with
the newly fitted parameters in this study reported in bold
with corresponding standard deviations. Since the study
showed little difference between fresh and aged nanoparti-
cles, neither for the CeO2 characterization, nor for their
biodistribution, the same model parameters could be used
for both fresh and aged nanoparticles.
Evaluation of the model and identification of key
parameters
The same model evaluation approach was applied as in
Li et al. [23]: we first visually inspected the output and
then determined the deviation from the line of unity be-
tween the log10 of measured and predicted values [44],
and calculated the corresponding R2 and squared geo-
metric standard deviation from the unity line.
Sensitivity analysis
The sensitivities to each model parameter were mea-
sured by the relative change in area under the mass-time
curve (AUC) divided by the relative change in each input
parameter p taken at 1 %:
Sensitivity coefficient ¼ dAUC=AUC
dp=p
The sensitivity coefficients were calculated at 180 h
after the start of exposure.
Results
Characterization of CeO2 nanoparticles
A typical real time characterization of particle size distribu-
tion during an exposure study, as measured using the
SMPS, is shown in Fig. 3a, for the second experiment of
aged nanoparticles. The individual distributions are shown
for 60, 120, and 180 min after the start of the experiments
as well as the average particle size distribution over the
240 min of particle generation. The size distributions indi-
cate slightly bimodal behavior with peaks around 25 and
90 nm, with ~90 % of the particles less than 200 nm in size.
The estimates for the particle diameters are based on the
equivalent diameter of a spherical particle with the same
mass. The same size distribution trends were observed for
both the fresh and aged particles. Additional details on the
time history of the particle size distribution are provided by
(Fatouraie et al.: Combustion-generated particle synthesis
and delivery system for inhalation exposure studies:case
study for ceria nanoparticles, submitted). After converting
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Table 1 Description and values for non-inhalation specific pharmacokinetics parameters. Values in bold are fitted a
Parameter (unit) Description Generic values b Spleen (s) Liver (l) Lungs (lu) Heart (h) Kidneys (k) GI tract (gi) Brain (br) Rest of the
body (rest)
Blood
(blood)
Wt/WB (unitless)
b % of organ weight to
body weight
- 0.0031 0.0396 0.0047 0.0034 0.0094 0.044 0.0053 0.84 0.0498
Wt,b/Wt
(unitless) c
% of capillary blood in
organ to organ weight
- 0.225 0.156 0.1 0.175 0.316 0.1 0.07 0.017 -
frQt (unitless)
d Fraction of cardiac output
to organ
- 0.0146 0.0465 1 0.051 0.141 0.213 0.02 0.514 1
Nt (# per g)
d Phagocytizing cells
number per organ weight
- 2.08 × 108 2.72 × 107 2.69 × 106,
3.90 × 106 ±
3.71 × 102 g
7.60 × 104 9.90 × 104 5.06 × 105 ±
2.22 × 103
3.06 × 105 8.11 × 106 1.85 × 103
Mcap (μg per #) f Maximum uptake capacity
in individual phagocytizing
cells
5.52 × 10−7 ±
6.98 × 10−11
- - - - - - - - -
χα (unitless) f Permeability coefficient
between blood and tissue
7.76 × 10−1 ±
2.14 × 10−4
Generic Generic Generic Generic Generic Generic 6.75 × 10−7 ±
8.84 × 10−11
1.71 × 10−2 ±
6.54 × 10−7
-
P (unitless) f Partition coefficient
between tissue and blood
2.09 × 10−1 ±
9.83 × 10−7
Generic Generic Generic Generic Generic Generic Generic Generic 1
kab0 (per h)
f Maximum uptake rate by
phagocytizing cells
1.45 × 100 ±
4.62 × 10−5
5.18 × 10−1 ±
5.87 × 10−5
Generic Generic Generic Generic Generic Generic Generic Generic
kde (per h)
f Desorption rate by
phagocytizing cells
5.30 × 10−19 ±
1.24 × 10−17
Generic Generic Generic Generic Generic Generic Generic Generic Generic
CLEe (per h) Clearance rate to excreta - - 1.52 × 10
−3 ±
6.97 × 10−6
- - 3.26 × 100
± 2.70 × 10−3
1.41 × 10−1 ±
8.42 × 10−7
- - -
frβ (unitless)
e, f Fraction of capillary blood
of organs left when
analyzed
0.144 Generic Generic Generic Generic Generic Generic 0.371 Generic -
a “-” stands for not applicable
b Values were obtained by from Wenger et al. [45] except for the GI tract, which was obtained from Bernareggi and Rowland [42]
c Values were obtained from literature estimates of the percentage (w/w) of capillary blood in the organs [41] except for lungs and GI tract, which were estimated by the authors
d Values obtained from literature [15, 42, 43]
e Values obtained from Carlander et al. [35]
f Mcap, χα, P, kab0, kde, frβ have generic values for most compartments. “generic” indicates the corresponding generic value for each parameter
g 2.69 × 106 is for the lungs interstitium, 3.90 × 106 ± 3.71 × 102 is for the pulmonary region of the lungs
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the number based concentrations to mass based concentra-
tions, the size distribution for all four experiments follow a
log-normal distribution (Additional file 2: Figure S1) with
the following geometric means and 95 % confidence inter-
vals: 146 nm (95 % confidence interval, 50 to 334 nm),
195 nm (95 % confidence interval, 66 to 334 nm), 174 nm
(95 % confidence interval, 61 to 338 nm), and 151 nm
(95 % confidence interval, 52 to 322 nm), for fresh 1, fresh
2, aged 1, and aged 2 experiments respectively.
The exposure concentrations based on filter pack
measurements of CeO2 nanoparticles for experiments
fresh 1, fresh 2, aged 1, and aged 2 were 172, 585, 483, and
439 μg/m3, respectively. During the fresh two experiment,
exposure levels varied between an initial period of
197 min at a lower exposure level (when a leak at the
exposure chamber was identified and repaired), and a sub-
sequent period of 163 min with a higher exposure level,
where 585 μg/m3 being the time-averaged concentration
for the entire 6 h of exposure. The duration of the other
three experiments was 4 h. The exposure concentrations
based on the SMPS measurements were 361 μg/m3,
1240 μg/m3 (during the latter 163 min of the test),
619 μg/m3, and 444 μg/m3, for the fresh 1, fresh 2, aged 1,
and aged 2 experiments, respectively. The SMPS based
concentrations are relatively consistent with the concen-
trations based on the filter packs measurements except for
the fresh 1 experiment. Based on the size distribution re-
corded by the SMPS, the exposure concentrations of
nanoparticles smaller than 70 nm for the fresh 1, fresh 2,
aged 1, and aged 2 experiments were 28.6 μg/m3, 39.8 μg/
Table 2 Description and values for inhalation specific pharmacokinetics parameters All values are fitted
Parameter (unit) Description Value
frua (unitless) Fraction of inhaled nanoparticles deposited in the upper airway 2.11 × 10
−1 ± 8.54 × 10−7
frtra (unitless) Fraction of inhaled nanoparticles deposited in the tracheobronochial region 1.75 × 10
−2 ± 1.23 × 10−7
frpul (unitless) Fraction of inhaled nanoparticles deposited in the pulmonary region 4.36 × 10
−2 ± 4.08 × 10−8
kgiab (per h) Absorption rate of GI tract 5.41 × 10
−3 ± 7.38 × 10−8
kuabr (per h) Transfer rate from upper airway to brain 8.36 × 10
−5 ± 1.34 × 10−9
kuagi (per h) Transfer rate from upper airway to GI tract lumen 3.35 × 10
−1 ± 2.24 × 10−6
ktragi (per h) Transfer rate from tracheobronchial region to GI tract lumen 5.52 × 10
−3 ± 1.22 × 10−6
kpulmtra (per h) Transfer rate of inactive phagocytizing cells from pulmonary region to tracheobronchial region 8.65 × 10
−4 ± 4.74 × 10−7
klupi (per h) Transfer rate from pulmonary region to interstitium of lungs 1.26 × 10
−1 ± 3.47 × 10−5
kluip (per h) Transfer rate from interstitium of lungs to pulmonary region 1.12 × 10
−6 ± 2.49 × 10−6
delaygi (h) Time delay for nanoparticles to travel from respiratory system to GI tract 1.88 × 10
0 ± 8.02 × 10−5
delayf (h) Time delay for nanoparticles in feces to be excreted out 7.9 × 10
0 ± 1.04 × 10−1
Fig. 3 Characterization of the CeO2 nanoparticles. a SMPS results for number size distribution for CeO2 nanoparticles in the aged 2 experiment at
60, 120, and 180 min after the start of exposure. The average number size distribution for the 240-minute duration of the exposure study is
presented in the panel and in the inset (log scale) where the error bars represent one standard deviation of the number size distribution for each
particle size bin. b XRD spectra presented as a function of the XRD scattering angle 2θ of the powder sample collected on the impactor surface.
The reference XRD spectra for CeO2 is presented for comparison. The labels correspond to the peak angles. c Bright field TEM images of CeO2
particles at two magnifications
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m3 (during the latter 163 min of the test), 27.0 μg/m3, and
36.5 μg/m3, respectively, showing less variation between
the experiments than the total mass concentrations, which
are biased to heavier/larger particles.
Bulk powder samples collected on the impactor sur-
faces were used for XRD analysis and to determine the
phase, composition and average crystallite size of the
nanoparticles. Because the nanoparticles for XRD ana-
lysis were taken from the impactor surface (to acquire
sufficient material for analysis), the results are biased to
larger particle sizes than the particles transported to the
exposure chamber. However, the results are expected to
be consistent for composition and phase data. Typical
XRD spectra for fresh nanoparticles are presented in
Fig. 3b. All peaks in the spectra correlate well with the
crystallographic reference database for CeO2 [Powder
diffraction file, compiled by JCPDS. International Centre
for Diffraction Data, Swarthmore, PA (1990)]. The refer-
ence spectra are provided in Fig. 3b for comparison.
Average crystallite size was determined based on the
spectral peak broadening according to the Scherrer
equation using the methods described in Bakrania et al.
[29]. Detailed analysis was performed for two of the
XRD features. An average crystallite size of 6.67 ±
0.06 nm was determined, which is as expected, slightly
higher than the TEM values of primary particle
diameter.
TEM images are presented in Fig. 3c for typical fresh
nanoparticles. The images show the nanoparticles were
highly agglomerated structures which consisted of small
primary particles. TEM image analysis indicates the
average diameter of the primary particles was typically
2–3 nm. Consistent with the SMPS data, analysis of the
TEM images revealed no significant differences between
the fresh and aged particles in terms of primary particle
size or the agglomerated morphology.
Together the SMPS, XRD and TEM data indicate both
fresh and aged nanoparticles are agglomerates of small
primary particles of CeO2 approximately 2–3 nm in size,
and the agglomerate dimensions (based on the SMPS
data) span a size distribution up to ~200 nm in size.
Biodistribution of CeO2 nanoparticles
Table 3 summarizes the concentrations of CeO2 nano-
particles found in the organs. The lungs consistently had
the highest concentrations for all experiments, followed
by the feces and the GI tract. The findings from the pilot
study focused on feces showed (Additional file 3), com-
pared to the first day post exposure, concentrations of
CeO2 nanoparticles in the feces were reduced by 97 %
on the fourth day post exposure and remained stable at
low concentrations afterwards, as also observed by He
et al. [13]. The evolution of the concentration in the GI
tract also showed a decreasing trend (Table 3), although
not as significant a rate of decay as observed for the
feces. For the extrapulmonary organs (i.e., the blood,
kidneys, heart, brain, liver, and spleen), different trends
were observed. The concentrations in the blood showed
a slight decrease over time. Concentrations in the spleen,
liver, and kidneys rose steadily while concentrations in
heart remained relatively stable. CeO2 nanoparticles
were detected in the olfactory bulb and in the brain for
the fresh 1 and fresh 2 experiments, while being mostly
below the detection limit for the aged 1 experiment. The
concentrations in the olfactory bulb were exceptionally
high for the fresh 2 experiment (higher than in other
extrapulmonary organs by one order of magnitude). For
the aged 2 experiment, the brain had the highest con-
centrations among all experiments, while the concentra-
tions in the olfactory bulb were below the detection
limit except 1-day post exposure. The urine also had
concentrations of CeO2 nanoparticles comparable to the
blood concentration 1-day post exposure except for the
fresh 2 experiment. The decreasing lung concentrations
and the increasing concentrations in extrapulmonary or-
gans suggests the CeO2 nanoparticles deposited in the
lungs could serve as a secondary source of exposure to
the extrapulmonary organs, either by direct transfer
from the lungs or through an indirect route via the GI
tract. Detailed concentrations for each rat are given in
Additional file 4.
The Shapiro-Wilk test showed the data was mostly fol-
lowing normal distribution. The Student t-test showed
only the liver at 15-min post exposure, olfactory bulb at
1-day post exposure, and the blood for all three time
points had p-value < 0.05. The null hypothesis of no sig-
nificant differences between the biodistribution of fresh
and aged nanoparticles for each time point and organ
was therefore considered retained for all organs except
for blood. For blood, the difference was due to the much
higher normalized concentration in fresh 1 experiment,
which could be the result of a higher sub-fraction of
nanoparticles smaller than 70 nm found in that experi-
ment (17 %, at least twice higher than the other
experiments).
Combining the concentrations with the different organ
weights, the masses of CeO2 nanoparticles were calcu-
lated and mass balance analysis was performed. The re-
sults are presented in Fig. 4, with Fig. 4a showing the
total amount of nanoparticles recovered at 1-day post-
exposure in comparison with the calculated total intake,
and Fig. 4b showing the total amount of nanoparticles
recovered in the extrapulmonary organs at 15 min, 1-
day, and 7-day post-exposure in comparison with the
sub-fraction of inhaled nanoparticles that were less than
70 nm as identified using the SMPS size distribution.
The absolute recovered mass based on the ICP-MS
measurements was approximately the same for all
Li et al. Particle and Fibre Toxicology  (2016) 13:45 Page 10 of 20
Table 3 Measured concentrations of CeO2 nanoparticles at different post exposure time (ng/g)
a, b
Organ Fresh 1, filter packs based concentration
172 μg/m3, SMPS based <70 nm
concentration 27.9 μg/m3
Fresh 2 c, filter packs based concentration
585 μg/m3, SMPS based <70 nm concentration
38.9 μg/m3
Aged 1, filter packs based concentration
483 μg/m3, SMPS based <70 nm
concentration 26.4 μg/m3
Aged 2, filter packs based concentration
439 μg/m3, SMPS based <70 nm
concentration 35.6 μg/m3
15 min 1 day 7 day 15 min 1 day 7 day 15 min 1 day 7 day 15 min 1 day 7 day
Blood 3.10 ± 0.88 2.90 ± 0.22 1.85 ± 0.07 2.36 ± 0.33 2.32 ± 0.11 2.10 ± 0.35 1.50 ± 0.13 1.76 ± 0.24 0.91 ± 0.33 1.16 ± 0.29 0.57 ± 0.09 0.91 ± 0.35
Lungs 317 ± 129 225 ± 31 93.9 ± 129 1593 ± 144 935 ± 1317 1014 ± 1417 1307 ± 391 495 ± 469 775 ± 325 953 ± 758 1421 ± 250 929 ± 317
Spleen 0.92 ± 0.74 0.21 ± 0.07 2.26 ± 2.73 0.12 ± 0.05 0.46 ± 0.16 3.14 ± 4.39 0.34 ± 0.25 0.27 ± 0.02 0.38 ± 0.09 1.19 ± 0.07 1.55 ± 0.46 1.92 ± 0.24
Liver 0.49 ± 0.12 1.47 ± 0.22 6.65 ± 4.62 0.95 ± 0.22 1.55 ± 1.49 4.46 ± 5.63 0.31 ± 0.21 1.27 ± 0.99 6.36 ± 2.81 0.32 ± 0.15 1.63 ± 0.55 3.57 ± 0.64
Kidneys 0.22 ± 0.06 0.99 ± 0.35 1.67 ± 0.43 0.94 ± 0.03 1.41 ± 0.81 3.47 ± 3.21 0.24 ± 0.09 0.58 ± 0.11 1.73 ± 0.40 1.20 ± 0.16 1.93 ± 0.18 2.96 ± 0.54
GI tract - - - - - - 63.0 ± 30.4 1.26 ± 12.8 9.78 ± 4.95 34.4 ± 13.4 24.4 ± 20.4 8.95 ± 6.19
Heart 0.13 ± 0.03 0.37 ± 0.38 0.33 ± 0.06 0.61 ± 0.14 0.56 ± 0.13 0.66 ± 0.28 0.25 ± 0.19 0.49 ± 0.45 0.25 ± 0.07 1.36 ± 0.13 1.32 ± 0.15 1.47 ± 0.05
Brain 0.16 ± 0.01 5.55 ± 8.91 0.77 ± 0.11 1.11 ± 0.17 0.95 ± 0.03 1.42 ± 0.19 0.34 d BDL BDL 1.64 ± 0.47 1.83 ± 0.76 1.41 ± 0.29
Olfactory
bulb
0.69 ± 0.07 0.84 ± 0.08 0.69 ± 0.29 13.0 ± 10.6 5.92 ± 3.65 4.69 ± 1.71 BDL BDL BDL BDL 0.92 d BDL
Feces - 91.6 ± 4.3 - - 769 ± 431 - - 672 ± 431 - - 656 ± 117 -
Urine - 5.79 ± 3.37 - - - - - 1.66 ± 1.26 - - 1.98 ± 2.06 -
a All values displayed are mean ± standard deviation (n = 3)
b “BDL” stands for below detection limit; “-” stands for no samples
c The exposure duration for experiment fresh 2 was 6 h, instead of 4 h for all other experiments. Please refer to text for more details
d Only one sample was above detection limit
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experiments but the fresh 1 experiment. The total esti-
mated inhaled amount based on the filter pack measure-
ments after the cascade impactor filter with the final
stage cut-off of 0.5 μm was lowest for the fresh 1 experi-
ment, the highest for the fresh 2 experiment, and was
intermediary for the aged 1 and aged 2 experiments,
with total inhaled mass estimates of 5.13, 26.69, 14.40,
and 13.04 μg, respectively (see Fig. 4a). One-day post ex-
posure, feces dominated the recovered masses (71–90 %)
due to the high weight of the feces and the high concen-
trations of CeO2 nanoparticles (Fig. 4a). Although higher
in concentration, the lungs had lower weights than the
feces and therefore contributed less than the feces to the
total recovered mass of CeO2, while remaining
substantial (7–18 %). The urine and extrapulmonary or-
gans both contributed between 4 and 6 % of the total re-
covered mass in the fresh 1 experiment, but contributed
less than 0.5 % of the total recovered mass for the other
experiments. Previous nanoparticle biodistribution stud-
ies have seldom included the GI tract in the analysis but
the mass balance on the fresh nanoparticle exposure
studies suggested that the GI tract could be accumulat-
ing a large proportion of the inhaled nanoparticles. To
test this hypothesis, we analyzed the GI tract for the
aged particle exposure studies. Nanoparticles found in
the GI tract for the aged experiments contributed to 2
to 3 % of the total recovered mass, which is an order of
magnitude higher than the total amount recovered in all
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Fig. 4 Biodistribution of CeO2 nanoparticles in different organs. a Mass balance of recovered amount 1-day post exposure compared with calculated
total inhaled amount of nanoparticles based on the filter pack measurements after the cascade impactor (equipped with a final cut-off of 0.5 μm), error
bars show one standard deviation of the feces data. b Evolution of the total nanoparticles mass in the extrapulmonary organs compared with the
inhaled mass of nanoparticles less than 70 nm in size, identified using the SMPS measurements. The three bar stacks represent the data from
15-min, 24-h, and 7-day post exposure, respectively, from left to right
Li et al. Particle and Fibre Toxicology  (2016) 13:45 Page 12 of 20
extrapulmonary organs for the same experiments at 1-
day post exposure. The total inhaled mass of nanoparti-
cles smaller than 70 nm, based on the SMPS measured
concentrations for the fresh 1, fresh 2 (corrected for the
leakage), aged 1, and aged 2 experiments were 0.85, 0.82,
0.81, and 1.06 μg, respectively (Fig. 4b). Interestingly, the
absolute amounts of nanoparticles found in the extrapul-
monary organs varied by less than 65 %, while the total
estimated inhaled amount based on filter pack measure-
ments varied by a factor of five. The results may suggest
only the fraction of CeO2 nanoparticles that are small
enough can penetrate the alveolar wall and find their
way into the extrapulmonary organs. The muscle, skin,
fur, and skeletons of the rats were not analyzed for CeO2
contents. The unrecorded mass of nanoparticles in these
tissues could explain the lower than 100 % recovery for
the experiments.
PBPK model simulation
Figure 5 shows the evolution of the amount of nanopar-
ticles predicted by the PBPK model and compares the
results with the observed experimental data. The model
results are able to reproduce the different experimentally
observed trends. The CeO2 nanoparticle levels in the
lungs increase rapidly during the exposure period, peak
at the end of exposure, and then slowly decrease over
time. After a period of delay, cumulated CeO2 nanopar-
ticles amounts in the excreted feces increase rapidly
until around the third day after exposure, before enter-
ing a phase of much slower increase [45]. The total
amount of CeO2 nanoparticles in the extrapulmonary
organs is much smaller than the amount in the feces
and lungs. This amount increases quickly during the ex-
posure period like what is seen in the lungs, but the
amount keeps increasing after exposure until the end of
the experiment for the spleen, liver, and kidneys (Fig. 5b
and Additional file 5: Figure S3) in contrast to the de-
creasing levels in the lungs. The amount of CeO2 nano-
particles in the GI tract reach a maximum shortly after
exposure and then decrease sharply, corresponding to
the same time a large increase of CeO2 nanoparticles is
observed in the feces (Fig. 5c and d). The model
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underestimates the amount of CeO2 nanoparticles in the
feces and overestimates the decrease rate of CeO2 nano-
particles in the GI tract after exposure.
When examining individual organs (Additional file 5),
the model suggests the CeO2 nanoparticles are almost
exclusively (over 99 %) stored in the PCs in all organs
except for the blood for the entire time span of the
study. This indicates according to the model, the PCs in
the organs are not yet saturated. For the blood, the
transfer of CeO2 nanoparticles from the alveolar region
to the blood during the exposure period overwhelms the
uptake by the PCs in the blood. After exposure ends,
there is still a considerable amount of CeO2 nanoparti-
cles not captured by the PCs in the blood, which is be-
cause the PCs in the blood are saturated due to their
low number. These “free” CeO2 nanoparticles in the
blood then circulate to the extrapulmonary organs and
are captured by the PCs in those organs over time.
As illustrated in Figs. 5 and 6, the model predictions
for the four experiments in this study agree generally
well with measured data (R2 on the log scale ranging
from 0.68 to 0.95). The GSD2 ranged from 3.9 to 22.8,
indicating the accuracies of the predictions of individual
data points are between a factor of 4 to 23 compared
with the variation of four orders of magnitude differ-
ences between the CeO2 loadings in all organs at all
times.
Table 4 summarizes the sensitivity of all parameters
that are both nanoparticle-specific and show a sensitivity
coefficient higher than 0.1 or lower than −0.1 in more
than one organ. The parameters that show high sensitiv-
ity (higher than 0.3 or lower than −0.3) in almost all or-
gans are the fraction of inhaled nanoparticles deposited
in the upper airway (frua), and the fraction of inhaled
nanoparticles in the pulmonary region (frpul). The feces
clearance rate from the GI tract (CLEfgi), the absorption
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rate of the GI tract (kgiab), the partition coefficient be-
tween the tissue and the blood (P), and the permeability
coefficient between the blood and tissues other than the
liver and the spleen (χrest) exhibit high sensitivity for
most extrapulmonary organs. The blood is very sensitive
to the maximum uptake capacity in individual PCs
(Mcap), but for all other organs this is not a very sensitive
parameter. The brain is very sensitive to the transfer rate
from the upper airway region to the GI tract (kuagi) while
the other organs are not sensitive. The maximum uptake
rate by the PCs (kab0) is particularly sensitive for the
spleen and urine.
Discussion
The experimental design of this study enabled compari-
son of freshly generated and UV-light aged CeO2 nano-
particles with other conditions that may affect the
characteristics of the nanoparticles held constant. As the
other conditions were well controlled, any differences in
the characteristics of the fresh and aged CeO2 nanoparti-
cles are solely explained by the UV-light aging process.
However, based on the results obtained from this study,
the size distribution, morphology, and crystalline struc-
ture of the fresh and aged CeO2 nanoparticles were simi-
lar. Other studies showed under irradiation, some
nanoparticles may have altered surface chemistry that
can result in different toxicity or behaviors in the envir-
onment [46, 47]. Within the uncertainty of the current
measurements, such effects were not apparent in the re-
sults for materials characterization or the biodistribution
of the CeO2 nanoparticles. Further experiments using
nanoparticles with controlled changes in surface chemis-
try would be of considerable interest to isolate the ef-
fects of surface chemistry. Also, considering CeO2
nanoparticles are used as additives to diesel fuel, another
aging condition relevant for CeO2 would be to age CeO2
nanoparticles with soot co-produced from the combus-
tion system. Such experiments could provide additional
insights on the aging process under conditions different
from the ambient urban environment and UV exposure
represented in this study. For example, previous studies
have found when CeO2 nanoparticles were produced
with other co-pollutants from diesel engines, the CeO2
nanoparticles tended to agglomerate with soot particles
instead of being freely dispersed [48, 49]. In addition,
other reactive atmospheric compounds such as isoprene
may also affect the result of the CeO2 aging process
[50]. The results of the characterization of the CeO2
nanoparticles in this study indicated the effects of aging
on morphology, size distribution and crystalline phase
were minimal when CeO2 nanoparticles were subjected
to a representative ambient urban environment, but not
co-produced with soot. This suggests that soot is a crit-
ical component to the aging of CeO2 nanoparticles ob-
served in previous studies.
Performing mass balance analysis is critical to ensure
the majority of the CeO2 nanoparticles inhaled were
accounted for in the biodistribution. More than half of
the recovered nanoparticles were found in the feces.
Data on the feces showed substantial variation that may
be caused by a number of factors such as the amount of
nanoparticles deposited on rats’ snout, whiskers and fur,
the possible subsequent grooming by the rats that may
lead to ingestion of externally-deposited nanoparticles
during and post exposure, and contamination of the col-
lected sample feces by rat fur. The high concentrations in
the urine samples could actually be the result of contam-
ination by the feces as urine and feces were in contact in
the metabolic cages before being analyzed. Additionally,
increased agglomeration of the nanoparticles may result
in increased deposition in the upper airway region and if
swallowed can lead to increased levels in the feces.
According to the filter packs measurements, experi-
ment fresh 1 had a lower concentration of CeO2 nano-
particles. This was due to the lower count of larger
nanoparticles in that particular experiment. The differ-
ent size distributions of the nanoparticles in this experi-
ment provided the opportunity to study the possible
Table 4 Sensitivity coefficients of important nanoparticle-specific parameters (four experiments averages, <−0.3 or >0.3 bolded)
Parameter Blood Lungs Liver Spleen Kidneys Heart Brain GI tract Urine Feces
CLEfgi
a −0.08 0.00 −0.65 −0.62 −0.64 −0.46 −0.17 −0.92 −0.66 0.08
Mcap 0.86 0.01 −0.13 −0.09 −0.12 −0.07 −0.02 −0.01 −0.16 0.00
kab0 −0.02 0.07 0.19 −0.75 0.14 0.10 0.02 0.00 −0.81 0.00
kgiab 0.08 0.00 0.69 0.66 0.67 0.49 0.18 0.03 0.70 −0.04
kuagi 0.00 0.00 0.01 0.01 0.01 −0.23 −0.72 0.00 0.01 0.02
P −0.05 0.00 0.52 0.49 0.48 0.34 0.12 0.04 −0.46 0.00
χrest b −0.05 0.00 −0.39 −0.39 −0.36 −0.27 −0.08 −0.02 −0.41 0.00
frua 0.08 0.00 0.69 0.66 0.68 0.67 0.98 0.92 0.70 0.97
frpul 0.06 0.76 0.42 0.42 0.43 0.42 0.00 0.05 0.44 0.00
a Clearance rate from GI tract to feces
b Permeability coefficient between blood to rest of the body
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effects of particle size on uptake and biodistribution.
Despite the differences in total inhaled dose among the
four experiments (up to a factor of five difference), the
amount of CeO2 recovered in all the extrapulmonary or-
gans was quite similar (within 65 % of each other). Add-
itionally, the amount of smaller CeO2 nanoparticles,
with sizes <70 nm based on the SMPS data, varied by
less than 31 %. Translocation across the alveolar epithe-
lial monolayer has been demonstrated in in vitro experi-
ments even for nanoparticles of primary particle size
one order of magnitude larger than those in this study
[51]. The higher degree of similarity between the
amount of CeO2 recovered in the extrapulmonary or-
gans and the amount of smaller sized nanoparticles
could indicate only the smaller nanoparticles enter from
the lungs and then travel to the extrapulmonary organs
via blood circulation. Previous studies have confirmed
this hypothesis [52, 53]. In addition, the overall translo-
cated fractions, defined as the total amount of CeO2 in
the extrapulmonary organs divided by the average amount
in the lungs, increased from 4.5 to 10 % between 15 min
and 7 days after exposure. This agrees well with a recent
finding on the kinetics of nanoparticle translocation across
the lung epithelial tissue barrier [26].
In this study, although the concentrations of CeO2
nanoparticles found in the brain and olfactory bulb were
not consistently above the detection limit, the detected
concentrations in the brain were of the same order of
magnitude as found in the blood. This could support the
hypothesis proposed by others that nanoparticles can
enter the brain through the olfactory bulb [54, 55].
Besides the feces, most of the recovered CeO2 nano-
particles were found in the lungs for all four experi-
ments in this study, which is consistent with previous
studies [8, 13, 14]. In contrast to He et al. [13], this study
showed higher amounts recovered in the feces than in
the lungs. The difference may be due to differences in
the exposure methods. He et al. used intratracheal instil-
lation and a bolus dose, which will limit nanoparticle de-
position outside the respiratory system and exclude the
possibility of ingestion intake to the GI tract from the
nanoparticles deposited externally on the snout and
whiskers. In this study, the concentrations of nanoparti-
cles found in the GI tract were at least an order of mag-
nitude higher than data reported by He et al. Among the
extrapulmonary organs, the liver and the blood had the
highest amount of CeO2 nanoparticles. The amount of
nanoparticles in the liver, spleen, and kidney increased
over time; the amount in the blood decreased over time;
and the amount in the heart and brain stayed relatively
constant. These trends generally agree with previous
pulmonary studies [13, 14] although the blood concen-
tration reported by He et al. [13] kept increasing and the
spleen results from Geraets et al. [14] did not show any
clear trend as a function of time. Aalapati et al. [8] ex-
posed mice to CeO2 nanoparticles daily for 4 weeks and
examined the contents in different organs 2 and 4 weeks
after the last exposure. They found a steady decrease in
nanoparticle concentrations in both the lungs and the
extrapulmonary organs. CeO2 nanoparticles might have
been cleared on a longer time frame. However, this de-
crease was not found by He et al. [13] after 4 weeks of
instillation in their study nor in the current work in the
1-week post exposure measurements. Nevertheless, the
nanoparticles in the above mentioned studies are not
exactly the same in terms of size and other characteris-
tics and this difference could contribute to the varying
results observed by different researchers.
Using diameters of the nanoparticles obtained from
the SMPS measurements, our fitted values for the de-
position fractions in the tracheobronchial and pulmon-
ary regions are lower than that calculated from the
Multiple-Path Particle Dosimetry Model (MPPD v2.11)
while the deposition fraction in the upper airway region
is higher (Additional file 2). This can be explained by the
likelihood of agglomeration of nanoparticles when in-
haled. The size of the agglomerate could increase and
therefore increase deposition in the upper airway, and
decrease deposition in the tracheobronchial and pul-
monary regions.
The PBPK model in this study accounts for multiple
physiological mechanisms to predict and explain the dy-
namics of the CeO2 nanoparticle levels in different or-
gans. In contrast to Bachler et al. [25], the PBPK model
developed in this work indicates CeO2 nanoparticle ex-
cretion in the feces predominantly originates from the
GI tract lumen as a result of mucociliary clearance, not
biliary excretion from the liver. This pathway is also sup-
ported by the high concentrations of nanoparticles found
in the GI tract samples, which were generally one or two
orders of magnitude higher than the concentrations
found in the liver. The sources of nanoparticles in the
GI tract lumen are a mixture of biliary excretion from
the liver, and the transfer of either free nanoparticles or
saturated PCs from the upper airway and pulmonary re-
gion by mucociliary movement to the larynx where the
nanoparticles or saturated PCs are then swallowed to
the GI tract. It is suspected the mucociliary clearance of
nanoparticle-loaded PCs is responsible for the continu-
ous excretion throughout the study. This transport of
nanoparticle-saturated PCs from the lungs to the GI
tract then to the feces is also the major contributor of
the slow decrease of CeO2 nanoparticles out of the lungs
and a widely accepted clearance route for inhaled nano-
particles [53, 56, 57]. Due to limited data as a function
of time, the dynamics of the nanoparticles in the GI tract
predicted by the model which included a rapid increase
shortly after exposure followed by a rapid decrease
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cannot be verified. It would be of interest to have finer
time resolution data on the short term after inhalation
exposure for the GI tract data to confirm if the model
predictions are true. The underestimate of the amounts
of CeO2 nanoparticles in the feces and overestimate of
the decrease rate of CeO2 nanoparticles in the GI tract
after exposure by the model could be explained by not
having a route to simulate the possible ingestion of
nanoparticles after inhalation exposure, when the ani-
mals might have licked their furs that were deposited
with nanoparticles. The PBPK model predicts the major-
ity of the nanoparticles in the lungs are captured by the
PCs in the pulmonary region. This agrees well with
microscopic evidence from both intratracheal instillation
of silver nanoparticles [53] and whole body inhalation
exposure of CeO2 nanoparticles [58].
According to the PBPK model, the majority of the
nanoparticles entering the blood are coming from the
uptake of the nanoparticles in the pulmonary region
during the exposure period. After exposure, some of the
nanoparticles transported to the GI tract may be
absorbed before being excreted during the fecal reten-
tion time. The absorbed nanoparticles from the GI tract,
together with small amounts of nanoparticles that are
desorbed from the PCs in the pulmonary region, enter
the systemic circulation and increase the levels of nano-
particles in the extrapulmonary organs or keep the
nanoparticle concentrations constant throughout the
study. The phagocytosis of nanoparticles is a well-
documented phenomenon [20, 21, 23] and supports the
model predictions that most of the CeO2 nanoparticles
are captured by PCs in the different organs. It is note-
worthy that the level of exposure in this study is much
lower than other CeO2 nanoparticle pulmonary exposure
studies [8, 13, 14]. The concentrations in the extrapul-
monary organs were also much lower than for studies
with intravenously injected nanoparticles [10, 11, 45].
Thus, the PCs in all organs including the pulmonary re-
gion in the lungs are not saturated in the current model,
leading to a limited amount of free nanoparticle that can
translocate in the organs.
Compared with the intravenous nanoparticle PBPK
model [23], this PBPK model is also sensitive to the par-
tition coefficients between the tissue and the blood, the
permeability coefficient between the blood and the tis-
sue, and the maximum uptake rate of the PCs. This
model however, is not sensitive to the PCs uptake cap-
acity except for the blood compartment. This is because
the blood level of nanoparticles in this inhalation study
is far lower than the level in the intravenous injection
experiment the previous model built upon. Therefore,
the PCs in this study are far from being saturated, mak-
ing the model insensitive to the PCs uptake capacity. As
shown in the results, the model is sensitive to the
clearance rate to the feces from the GI tract and the ab-
sorption rate of the GI tract. This implies the import-
ance of the GI tract in the biodistribution of inhaled
nanoparticles. The fractions of inhaled nanoparticles to
the upper airway and pulmonary region are directly re-
lated to the size of the nanoparticles and are both among
the most sensitive parameters of this model. This sup-
ports the expected conclusion that size is one of the
most important properties of nanoparticles in regards to
their biodistribution via inhalation. In contrast, the
model is far less sensitive to the deposition fraction of
inhaled nanoparticles to the tracheobronchial region.
This is because the tracheobronchial region is neither an
important point of entry nor a significant point of exit
for the nanoparticles and only acts as a transitional node
between the upper airways, the pulmonary region, and
the GI tract.
Most PBPK models for nanoparticles are only applicable
to intravenous injection [16–19, 23]. Our model is one of
the few existing PBPK models that can predict the biodis-
tribution of inhaled nanoparticles [25–27], and advances
the field by taking into account the dynamic of nanoparti-
cles in the feces directly excreted from mucociliary clear-
ance from the lungs, which has been shown to be a major
pathway for nanoparticles in this study and in the study
by He et al. [13]. Nevertheless, our model also has some
limitations when compared with the experimental results
of this study. First, the amount of CeO2 nanoparticles in
the liver is systematically underestimated at the end of this
study. Our model could not predict an increase over
time large enough to reach the measured levels 7-day
post exposure (Additional file 5). Certain physiologic
pathways may have been disregarded that cause this in-
crease in the liver. For example, the nanoparticles may
undergo endocytosis by the M cells in the GI tract for a
period of time before being exocytosed and may be in
contact with the GI tract wall [59]. This may create a
delayed effect for the nanoparticles to be absorbed by
the GI tract and make the nanoparticles in the GI tract
a source that can slowly release free nanoparticles over
time. Not including lymph nodes in the model may also
play a role in the limitation of this PBPK model, as
nanoparticles taken up by the lymph nodes can theoret-
ically have delayed entry to the blood system via vena
cava [60, 61].
Another limitation of the study is the large variation in
some of the experimental data. The PBPK model is able
to predict individual data points within one order of
magnitude. However, some of the measured data dis-
played large variations identified by large standard devia-
tions (see Table 3). The variation in the measured data
could be caused by the individual behavior of the rats
during and post exposure which can result in different
intake of CeO2 nanoparticles.
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Conclusions
CeO2 nanoparticles were generated before being inhaled
by rats in one integrated system in this study. Character-
izations of fresh and aged nanoparticles, where the aged
nanoparticles were exposed to UV light and urban air
environments before inhalation, showed little differences
in size distribution, morphology, or crystalline structure.
The biodistribution of fresh and aged CeO2 nanoparticles
followed the same patterns, with the highest amounts re-
covered in the feces and the lungs. The slow decrease of
nanoparticle concentration in the lungs is explained by
clearance to the GI tract and then to the feces. For the
extrapulmonary organs, the level of nanoparticles in the
blood reached a maximum at the end of exposure and
then decreased. The PBPK model successfully predicted
the dynamic of the CeO2 nanoparticles in the various or-
gans measured in this study. The model suggests most of
the nanoparticles were captured by PCs, which agrees
with the literature. When applying this model to other
nanoparticle inhalation studies, the exposure conditions
including the size distribution of the nanoparticles should
be clearly defined as these would affect model predictions.
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